NASDAQ:STAA - STAAR Surgical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $36.42 +1.25 (+3.55 %) (As of 02/18/2019 11:55 AM ET)Previous Close$35.17Today's Range$34.9615 - $36.4452-Week Range$13.60 - $54.00Volume333,483 shsAverage Volume400,288 shsMarket Capitalization$1.61 billionP/E Ratio3,642.00Dividend YieldN/ABeta1.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in approximately 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California. Receive STAA News and Ratings via Email Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Ophthalmic goods Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:STAA Previous Symbol CUSIP85231230 Webwww.staar.com Phone626-303-7902Debt Debt-to-Equity Ratio0.01 Current Ratio5.35 Quick Ratio4.76Price-To-Earnings Trailing P/E Ratio3,642.00 Forward P/E Ratio404.67 P/E GrowthN/A Sales & Book Value Annual Sales$90.61 million Price / Sales17.74 Cash Flow$0.0906 per share Price / Cash Flow402.02 Book Value$1.04 per share Price / Book35.02Profitability EPS (Most Recent Fiscal Year)$0.01 Net Income$-2,130,000.00 Net Margins3.17% Return on Equity14.80% Return on Assets10.15%Miscellaneous Employees353 Outstanding Shares44,132,000Market Cap$1.61 billion OptionableOptionable STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions What is STAAR Surgical's stock symbol? STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA." How were STAAR Surgical's earnings last quarter? STAAR Surgical (NASDAQ:STAA) announced its quarterly earnings results on Wednesday, October, 31st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.06. The medical instruments supplier had revenue of $31.77 million for the quarter, compared to analyst estimates of $30.10 million. STAAR Surgical had a net margin of 3.17% and a return on equity of 14.80%. During the same quarter in the previous year, the firm posted $0.03 EPS. View STAAR Surgical's Earnings History. When is STAAR Surgical's next earnings date? STAAR Surgical is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for STAAR Surgical. What price target have analysts set for STAA? 4 Wall Street analysts have issued 12-month price objectives for STAAR Surgical's stock. Their predictions range from $21.00 to $55.00. On average, they anticipate STAAR Surgical's share price to reach $43.3333 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View Analyst Price Targets for STAAR Surgical. What is the consensus analysts' recommendation for STAAR Surgical? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical. What are Wall Street analysts saying about STAAR Surgical stock? Here are some recent quotes from research analysts about STAAR Surgical stock: 1. According to Zacks Investment Research, "Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. " (11/8/2018) 2. Canaccord Genuity analysts commented, "We view the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the US market now fully accessible to STAA. While the near term now looks even brighter, we think the firm’s longer-term potential, both with presbyopia (a ~1.5M-patient annual TAM by company estimates) and with full entry into the US market (the second-largest refractive market in the world) acting as major growth drivers – drivers we expect to support sustained, double- digit organic growth into the next decade and beyond. We reiterate our BUY rating and increase our price target to $32 (9.1x EV/sales on 2020E)." (6/20/2018) Has STAAR Surgical been receiving favorable news coverage? Headlines about STAA stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. STAAR Surgical earned a coverage optimism score of 1.6 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of STAAR Surgical's key competitors? Some companies that are related to STAAR Surgical include SWEDISH ORPHAN/S (SWTUY), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), STADA Arzneimittel (STDAF), NMC Health (NMC), Amarin (AMRN), Syneos Health (SYNH), athenahealth (ATHN), Hikma Pharmaceuticals (HKMPF), Penumbra (PEN), GALAPAGOS NV/S (GLPG), ICU Medical (ICUI), United Therapeutics (UTHR), DiaSorin (DSRLF) and HYPERA S A/S (HYPMY). Who are STAAR Surgical's key executives? STAAR Surgical's management team includes the folowing people: Ms. Caren L. Mason, CEO, Pres & Director (Age 65)Ms. Deborah Andrews, Chief Financial Officer (Age 62)Dr. Keith Holliday, Chief Technology Officer (Age 56)Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 57)Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations - Europe & China (Age 54) Who are STAAR Surgical's major shareholders? STAAR Surgical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.05%), Baillie Gifford & Co. (3.86%), Northern Trust Corp (1.20%), Millennium Management LLC (1.12%), Defender Capital LLC. (1.08%) and Geode Capital Management LLC (0.92%). Company insiders that own STAAR Surgical stock include Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Institutional Ownership Trends for STAAR Surgical. Which institutional investors are selling STAAR Surgical stock? STAA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Kornitzer Capital Management Inc. KS, Hodges Capital Management Inc., Prudential Financial Inc., GSA Capital Partners LLP, Acadian Asset Management LLC, MetLife Investment Advisors LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Insider Buying and Selling for STAAR Surgical. Which institutional investors are buying STAAR Surgical stock? STAA stock was acquired by a variety of institutional investors in the last quarter, including Defender Capital LLC., Baillie Gifford & Co., Stanley Laman Group Ltd., First Trust Advisors LP, Dimensional Fund Advisors LP, SG Americas Securities LLC, Pura Vida Investments LLC and Two Sigma Investments LP. View Insider Buying and Selling for STAAR Surgical. How do I buy shares of STAAR Surgical? Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is STAAR Surgical's stock price today? One share of STAA stock can currently be purchased for approximately $36.42. How big of a company is STAAR Surgical? STAAR Surgical has a market capitalization of $1.61 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe. What is STAAR Surgical's official website? The official website for STAAR Surgical is http://www.staar.com. How can I contact STAAR Surgical? STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected] MarketBeat Community Rating for STAAR Surgical (NASDAQ STAA)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 170 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 418MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: What are the components of an earnings report?